Newbury Pharmaceuticals AB (FRA:P52) Operating Income: €-2.42 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:P52 Newbury Pharmaceuticals AB FRA:P52
41 GF Score
Price €0.16
GF Value €0.20
! 6 Warning Signs
View Full Analysis

What is Newbury Pharmaceuticals AB Operating Income?

Newbury Pharmaceuticals AB FRA:P52 -10.37% 41 Operating Income is €-2.42 Mil as of Feb. 2026. GuruFocus rates FRA:P52 with a GF Score™ of 41/100 and a GF Value™ of €0.20. The stock has 6 warning signs investors should review.

Newbury Pharmaceuticals AB's Operating Income for the three months ended in Feb. 2026 was €-0.39 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Feb. 2026 was €-2.42 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Newbury Pharmaceuticals AB's Operating Income for the three months ended in Feb. 2026 was €-0.39 Mil. Newbury Pharmaceuticals AB's Revenue for the three months ended in Feb. 2026 was €0.80 Mil. Therefore, Newbury Pharmaceuticals AB's Operating Margin % for the quarter that ended in Feb. 2026 was -48.99%.

Newbury Pharmaceuticals AB's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Newbury Pharmaceuticals AB's annualized ROC % for the quarter that ended in Feb. 2026 was -23.89%. Newbury Pharmaceuticals AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was %.


Newbury Pharmaceuticals AB  (FRA:P52) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Newbury Pharmaceuticals AB's annualized ROC % for the quarter that ended in Feb. 2026 is calculated as:

ROC % (Q: Feb. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2025 ) + Invested Capital (Q: Feb. 2026 ))/ count )
=-1.56 * ( 1 - 0% )/( (6.247 + 6.812)/ 2 )
=-1.56/6.5295
=-23.89 %

where

Note: The Operating Income data used here is four times the quarterly (Feb. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Newbury Pharmaceuticals AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2025  Q: Feb. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.56/( ( (0 + max(-2.485, 0)) + (0 + max(-2.963, 0)) )/ 2 )
=-1.56/( ( 0 + 0 )/ 2 )
=-1.56/0
= %

where Working Capital is:

Working Capital(Q: Nov. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.883 + 0) - (0 + 0 + 3.368)
=-2.485

Working Capital(Q: Feb. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 1.023 + 0) - (0 + 0 + 3.986)
=-2.963

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Newbury Pharmaceuticals AB's Operating Margin % for the quarter that ended in Feb. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Feb. 2026 )/Revenue (Q: Feb. 2026 )
=-0.39/0.796
=-48.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Newbury Pharmaceuticals AB Operating Income Related Terms


Newbury Pharmaceuticals AB Operating Income Historical Data

* Premium members only.

The historical data trend for Newbury Pharmaceuticals AB's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newbury Pharmaceuticals AB Operating Income Chart

Newbury Pharmaceuticals AB Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Operating Income
-0.55 -1.18 -1.53 -1.26 -1.85

Newbury Pharmaceuticals AB Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 -0.57 -0.91 -0.56 -0.39
FRA:P52
41GF Score
Newbury Pharmaceuticals AB FRA:P52
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newbury Pharmaceuticals AB Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of €-2.42 Mil mean?
Newbury Pharmaceuticals AB (FRA:P52) has a Operating Income of €-2.42 Mil as of Feb. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Newbury Pharmaceuticals AB and its competitors.
Is Newbury Pharmaceuticals AB's Operating Income too high?
Newbury Pharmaceuticals AB's current Operating Income is €-2.42 Mil. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Operating Income compare to ZTS and UTHR?
Newbury Pharmaceuticals AB's Operating Income of €-2.42 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Newbury Pharmaceuticals AB and its competitors. Newbury Pharmaceuticals AB's current Operating Income is €-2.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Newbury Pharmaceuticals AB (FRA:P52) has a current Operating Income of €-2.42 Mil. The stock's GF Value™ is €0.20, compared to a current price of €0.16 — trading 22.3% below its estimated fair value. The current Operating Income is €-2.42 Mil. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (FRA:P52), the current Operating Income is €-2.42 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newbury Pharmaceuticals AB (FRA:P52) Overvalued in 2026?

Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued. The current stock price of €0.16 is trading 22.3% below its estimated GF Value™ of €0.20.

Key valuation signals for FRA:P52:

  • Operating Income: €-2.42 Mil
  • GF Value™: €0.20 vs. price of €0.16 (22.3% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the FRA:P52 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Newbury Pharmaceuticals AB Business Description

Other Exchanges NEWBRY:Sweden
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score

Get the complete analysis for FRA:P52

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price
€0.20
GF Value